ASCO

The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies.  I’m Peter Goodwin wi

Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)

An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon

SAN FRANCISCO, CA—Adding the poly ADP ribose polymerase (PARP) inhibitor drug talazoparib to standard anti-androgen therapy with enzalutamide statistically significantly extended overall survival amon

CHICAGO—A 25 per cent risk reduction for esophageal cancer was found to be associated with prophylactic therapy consisting of a proton pump inhibitor (PPI) and aspirin in the phase three randomized AS

CHICAGO—Patients with resectable and “borderline resectable” pancreatic cancers treated with chemoradiation before surgery (followed by adjuvant chemotherapy) had significantly improved ou

CHICAGO—Patients with newly-diagnosed hormone-sensitive metastatic prostate cancer (mPC) who had prostate radiotherapy (RT) before their androgen deprivation therapy (ADT) lived longer than those trea

CHICAGO—Clinically targetable mutations were identified and patient subgroups pinpointed by whole genome sampling (WGS) of castration-resistant metastatic prostate cancer (mPC) in a study reportedatth

CHICAGO—A gene test that predicts for relapse in women with estrogen receptor positive early breast cancer can identify patients with low-risk disease who could safely avoid extending their endocrine

CHICAGO—Men who had breast-conserving therapy (BCT) including radiation for their early breast cancer lived longer than those who had total or partial mastectomy—with or without radiation—in findings

CHICAGO—A “cluster randomized controlled trial” of treatment for patients with advanced cancers found that the use of standardized geriatric assessments significantly increased the number

CHICAGO—Women and men were treated differently for the same tumor stages of head and neck cancer (HNC) and had different outcomes in a study with patients surveyed over a fifteen-year period in Santa

CHICAGO, IL—Patients whose non-small cell lung cancers (NSCLC) expressed more than one per cent of the programmed death ligand-1 (PD-L1) tumor proportion score (TPS) lived longer when treated with the

CHICAGO—Prophylactic contralateral (CLT) breast radiotherapy was associated with significantly fewer and delayed cases of breast cancer in women having standard therapy for their ipsilateral BRCA muta

SAN FRANCISCO— The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically determined progression-free survival in men whose metast

SAN FRANCISCO— A recently discovered molecular prognostic biomarker for clear-cell renal cell cancer has been validated and shown to indicate a four-fold increase in risk of adverse cancer-specific su

SAN FRANCISCO— Plasma and tumor biomarkers including FGF, C-KIT and VEG-F were found to yield prognostic information which could help guide therapies, according to research findings presented at the 2

SAN FRANCISCO— Gleason score at initial diagnosis was not predictive of response to abiraterone in patients with metastatic castration-resistant prostate cancer in a pooled analysis of three trials of

SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen depri

SAN FRANCISCO—A “guided missile” approach to treating metastatic, castration-resistant, taxane-refractory prostate cancer demonstrated success at the 2014 ASCO Genitourinary Cancers Sympos

SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “a

CHICAGO—Findings from an expanded phase I study in 107 patients with metastatic melanoma suggest that PD-1 inhibition with the novel agent nivolumab could bring extended remissions. Sarah Maxwell hear

CHICAGO— Overall survival improved by more than two-thirds in patients with metastatic melanoma randomised to have GM-CSF added to their ipilimumab therapy. A phase II study in 245 previously treated

CHICAGO—A new approach to dealing simultaneously with several of the identified molecular processes taking place in cancer has brought new prospects for extending life in patients with advanced non sm

CHICAGO—Adding cetuximab to first-line irinotecan chemotherapy for patients with metastatic colorectal cancer gave a median four months advantage in overall survival as compared with adding bevacizuma

CHICAGO—Patients with oropharyngeal cancer pose no risk of passing HPV infection to their spouses or partners — according findings presented at the 2013 meeting of the American Society of Clinical Onc

CHICAGO—The first drug to hold advanced uveal melanoma in check — doubling progression-free survival — was announced at the 2013 American Society of Clinical Oncology meeting in Chicago. Dr Richard Ca

ORLANDO, FLORIDA—Patients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr Ayal Aizer from the Brigham and Women’s Hospital, the Dana-Farber Ca

ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months — but have fewer side effec

ORLANDO, FLORIDA—Patients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr Ayal Aizer from the Brigham and Women’s Hospital,

ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months

Other headlines: – Raised incidence of HPV-associated cancers in the past 35 years in the United States. – Two new anticoagulants for the extended treatment of patients with unprovoked ven

CHICAGO—The outgoing president of ASCO, Dr Michael Link from Stanford University School of Medicine in California, answers questions from Peter Goodwin about the progress achieved in cancer clinical s

CHICAGO—Findings from a Phase III trial show that initial single-agent therapy with a new oral drug called afatinib prolongs progression- free survival in patients with advanced lung adenocarcinomas t

CHICAGO—At the Plenary Session of ASCO Maha Hussain MD, FACP of the University of Michigan in Ann Arbor presented results from a long-term, multicenter Phase III international clinical trial comparing

STOCKHOLM—The first specialist in pediatric oncology ever to hold office as President of the American Society of Clinical Oncology, Dr Michael Link — Professor of Pediatrics at Stanford University Sch

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology

Markus Heiss REFERENCE: ABSTRACT 5001, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 MARKUS HEISS, Klinikum Cologne, Merheim For patients with malignant ascites as a

Volker Diehl George Canellos Hodgkin’s Disease: 10-Year Results Show Further Benefit From Escalated BEACOPP Therapy REFERENCE: Abstract 8015, ASCO Annual Meeting Chicago June 1-5, 2007 VOLKER DI

Christian Manegold Roy Herbst More Support for Bevacizumab in Advanced Lung Cancer REFERENCE: Abstract LBA7514, ASCO Annual Meeting Chicago June 1-5, 2007 CHRISTIAN MANEGOLD, Heidelberg University, Ma

Aimery de Gramont Robert Mayer MOSAIC Study Six Year Results: Adjuvant Oxaliplatin Adds Survival Advantage for Patients with Stage III Colorectal Cancer REFERENCE: 4007, ASCO Annual Meeting Chicago Ju

Josep Llovet Robert Mayer Sorafenib The ‘New Standard’ for Advanced Liver Cancer REFERENCE: ABSTRACT 5 (Plenary Session), ASCO Annual Meeting Chicago June 1-5, 2007 JOSEP LLOVET, IDIBAPS H

Bernard Escudier Dean Bajorin Bevacizumab in Advanced Kidney Cancer: Another Treatment Gives Benefit in First Line REFERENCE: ABSTRACT 3, ASCO Annual Meeting Chicago June 1-5, 2007 BERNARD ESCUDIER, G

Ben Slotman Roy Herbst Prophylactic Cranial Irradiation: Fewer Brain Metastases, Longer Survival for Patients with Small Cell Lung Cancer REFERENCE: ABSTRACT 4, ASCO Annual Meeting Chicago June 1-5, 2

Lawrence Wickerham Invasive Breast Cancer Chemoprevention Trials Assessed REFERENCE: ABSTRACT Special Session; American Association for Cancer Research Centennial Meeting, April 14-18, Los Angeles LAW

Rachel Johnson Terry Mamounas William Gradishar Withhold Trastuzumab in Low-Risk Patients with HER-2 Positive Breast Cancer? REFERENCE: Abstract: 2090 RACHEL JOHNSON, Christie Hospital, Manchester Som

Francis Giles Ken Kaushansky Heather Leitch Nancy Berliner Corrado Tarella Vincent Rajkumar Robert Kyle Aurora Kinase BCR-ABL Inhibitor Beats T315-I Mutation in Patients with Chronic Myeloid Leukemia

Gordon McVie Martine Piccart Bella Kaufman Jean-Yves Douillard ESMO Congress Reviewed GORDON MCVIE, European Institute of Oncology, Milan In Istanbul, Gordon McVie gave his opinion about the achieveme

Robert Ozols William See Ruth Lupu Improving on Standard Treatment in Ovarian Cancer: Have We Hit a Wall? REFERENCE: Abstract 5002, 2006 ASCO Annual Meeting; N Engl J Med 2006, 354:34-43 ROBERT OZOLS,

Mark Socinski Bruce Johnson Neil Shah Doug Smith Sunitinib Multi-Targeted Oral Anti-Angiogenic Therapy Responses in Lung Cancer REFERENCE: Abstract 7001 Mark A. Socinski, Univerisity of North Carolina

Joan Houghton Elizabeth Barrett-Connor Fran Balkwill Carl Christophe Schimanski Adjuvant Anastrozole for Patients With Breast Cancer: Long-Term Safety Results From the ATAC Study REFERENCE: Lancet Onc

John Neoptolemos Wilko Weichert Christophe Nemos Pancreatic Cancer: Adjuvant Chemotherapy Improves Outlook for Patients with Resectable Tumors – ESPAC Trial Results REFERENCE: National Cancer Re

David Cunningham Kenneth MacDonald Mark Pomerantz Jorge Garcia REFERENCE: N Engl J Med 2006;355:11 David Cunningham, Royal Marsden Hospital The July 6th edition of the New England Journal of Me

Better Combine Chemotherapy with Radiation for Hodgkin’s Disease? Joachim Yahalom George Canellos REFERENCE: Education Session: Saturday June 3rd, 2006 ASCO Annual Meeting, June 2-6, Atla

Arlene Forastiere Everett Vokes Michael Skinner Mark Chambers Larynx Cancer: Concurrent Chemoradiotherapy: Best for Larynx Preservation REFERENCE: Abstract 5517 Arlene Forastiere, Sidney Kimmel Compre

Robert Ozols Lawrence Wickerham Patricia Ganz Jorma Paavonen Noah Kauff Robert Ozols of the Fox Chase Cancer Center in Philadelphia joins Derek Thorne to talk about the top presentations on cancer pre

Robert Mayer Thierry Facon Ibrahim Yakoub-Agha Peter Paschka Robert Mayer of the Dana-Farber Cancer Institute in Boston joins Derek Thorne to discuss the major hematologic malignancy news reported at

Dean Bajorin Robert Motzer Gary Hudes Marshall Posner Some major progress in kidney cancer and head and neck cancer was announced at the ASCO meeting in Atlanta, and the Audio Journal of Oncology has

Julie Gralow Charles Geyer Judith Bliss Robert Coleman Julie Gralow, from the Fred Hutchinson Cancer Research Center in Seattle, joins Derek Thorne to talk about the latest news from the ASCO annual m

George Canellos Carmela Pepe John Goldman Roy Herbst Sandra Horning George Canellos, from the Dana-Farber Cancer Institute in Boston, joins Derek Thorne to talk about the first day’s news at the

Bevacizumab: New Option for Breast Cancer REFERENCE: 5th European Breast Cancer Conference, Nice, 21st – 25th March 2006 Robin Zon, Michiana Hematology Oncology, South Bend, Indiana Bevacizumab

Myeloablative Radioimmunotherapy Eases Autologous Stem Cell Transplantations in Patients Age 60 years or Older With Relapsed or Refractory B-Cell Lymphoma ABSTRACT: 2005 American Society of Hematology

Tamoxifen After Chemotherapy Protects Premenopausal Patients with Breast Cancer ABSTRACT: J Clin Oncol 24:1322, 2006 Gordon McVie, European Institute of Oncology, Milan The use of tamoxifen after chem

Thalidomide Adds to Multiple Myeloma Chemotherapy Benefit in Older Patients ABSTRACT: Lancet 2006;367:825 George Canellos, Dana-Farber Cancer Institute, Boston The combination of thalidomide together

Reporting from: 8th International Conference on Malignant Lymphoma, Lugano; American Society of Clinical Oncology 38th Annual Meeting, Orlando; British Cancer Research Meeting, Glasgow Scientific Edit

Audio Journal of Hematologic Malignancy Volume 2 Number 1 Reporting from: American Society of Hematology Meeting, Philadelphia, December 6-10, 2002 Audio Journal of Hematologic Malignancy Volume 1 Num

Reporting from: – 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004 – New England Journal of Medicine – Journal of Clinical Oncology &#821

Reporting from: – 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004 – New England Journal of Medicine In this edition: At the ASCO conference Ga